ClinicalTrials.gg
Not yet recruitingNCT07142369Updated Jun 18, 2026

Synovial Fluid Withdrawal or PRP Injection For Acute ACL Tears and Cytokines

An interventional study of Synovial Fluid withdrawal at the preoperative clinic visit and Platelet-Rich Plasma (PRP) preparation and injection in Posttraumatic Osteoarthritis and Anterior Cruciate Ligament (ACL) Rupture, sponsored by Rush University Medical Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Rush University Medical Center · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The purpose of this study is to determine what effects the withdrawal of excess knee joint fluid or the injection of a factor from the blood has on swelling after a sudden anterior cruciate ligament (ACL) rupture of the knee.

Read the detailed description

The body responds to different stresses by releasing factors in the blood and fluids in response to stressors like injury, surgery or certain treatments. Some of these factors help heal and some make the injury and body swell (inflammation). In this study we want to see if the intervention of withdrawing fluid the knee or the addition of an enriched healing factor called platelet rich plasma (PRP) injected in the knee influences the body to produce healing factors in the knee joint fluid.

02

Conditions studied

  • Posttraumatic Osteoarthritis
  • Anterior Cruciate Ligament (ACL) Rupture

Keywords

  • osteoarthritis
03

In context

Rupture

78 studies on the registry are indexed under Rupture; 17 are open to participants now.

This study's planned enrollment of 99 is above the median of 71 across 44 interventional studies indexed under Rupture.

Browse Rupture studies →

Lead sponsor

Rush University Medical Center is the lead sponsor of 397 studies on the registry; 61 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 26 (81%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 - 50
  • English-speaking
  • Clinical evidence of ACL rupture with swelling
  • Participant must be undergoing ACL reconstruction surgery

Exclusion criteria

Exclusion Criteria:

  • Age \<18 or >50
  • Presentation >3 weeks after initial injury
  • Previous traumatic ipsilateral (same side) knee injury consistent with chronic ACL tear or prior ACL surgery
  • > Kellgren-Lawrence grade 2 changes on preoperative x-ray
  • History of hemophilia or inflammatory arthropathy (e.g., rheumatoid arthritis)
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
99 participants (estimated)

Study arms

  • Active comparator
    Two Synovial Fluid Withdrawals

    Subjects randomized to Arm 1 will have 2 synovial fluid withdrawals; one at the preoperative clinic visit and one at the time of surgery

    Procedure: Synovial Fluid withdrawal at the preoperative clinic visit · Procedure: Synovial fluid withdrawal at the time of surgery

  • Experimental
    Platelet-Rich Plasma (PRP) and Two Synovial Fluid Withdrawals

    Subjects randomized to ARM 2 will have 2 synovial fluid withdrawals one at the preoperative visit and one at the time of surgery. Platelet-Rich Plasma (PRP) preparation and injection will happen at the preoperative clinic visit.

    Procedure: Synovial Fluid withdrawal at the preoperative clinic visit · Procedure: Platelet-Rich Plasma (PRP) preparation and injection · Procedure: Synovial fluid withdrawal at the time of surgery

  • Other
    3mL Synovial Fluid Withdrawal and Synovial Fluid Withdrawal at the Time of Surgery

    Subjects randomized to Arm 3 will have 3mL withdrawal of synovial fluid at the preoperative visit and 1 synovial fluid withdrawal at the time of surgery

    Procedure: Synovial fluid withdrawal at the time of surgery · Procedure: 3mL synovial fluid withdrawn at the preoperative visit

Interventions

  • ProcedureSynovial Fluid withdrawal at the preoperative clinic visit

    Synovial Fluid withdrawal at the preoperative clinic visit

    Also known as: arthrocentesis

  • ProcedurePlatelet-Rich Plasma (PRP) preparation and injection

    Platelet-Rich Plasma (PRP) preparation and injection

    Also known as: platelet rich plasma

  • ProcedureSynovial fluid withdrawal at the time of surgery

    Synovial fluid withdrawal at the time of surgery

  • Procedure3mL synovial fluid withdrawn at the preoperative visit

    3mL synovial fluid withdrawn at the preoperative visit

06

What researchers measure

Primary outcomes

  1. Concentration of Collagen Type II Cytokine

    Breakdown cytokine found in damaged cartilage

    Time frame: Enrollment up to surgery

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Oct 2028, 25 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2025
First posted
Aug 26, 2025
StartEst.
Sep 2026
Primary completionEst.
Oct 2028
CompletionEst.
Dec 2028
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07142369
Collaborators
Arthroscopy Association of North America
Responsible party
Sponsor
First posted
Aug 26, 2025
Start date
Sep 2026 (estimated)
Primary completion
Oct 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jun 18, 2026

Study contacts

Adam Yanke, MD, PhD
Contact
cartilage.restoration@rushortho.com
(312) 432-2818
Jorge Chahla, MD, PhD
Contact
jorge.chahla@rushortho.com
Adam Yanke, MD, PhD
principal investigator · Associate Professor and Surgeon

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion